Megan Lyle

689 total citations
23 papers, 339 citations indexed

About

Megan Lyle is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Megan Lyle has authored 23 papers receiving a total of 339 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 8 papers in Molecular Biology and 6 papers in Immunology. Recurrent topics in Megan Lyle's work include Cancer Immunotherapy and Biomarkers (14 papers), Cutaneous Melanoma Detection and Management (8 papers) and Melanoma and MAPK Pathways (8 papers). Megan Lyle is often cited by papers focused on Cancer Immunotherapy and Biomarkers (14 papers), Cutaneous Melanoma Detection and Management (8 papers) and Melanoma and MAPK Pathways (8 papers). Megan Lyle collaborates with scholars based in Australia, United States and Italy. Megan Lyle's co-authors include Georgina V. Long, Alexander M. Menzies, Richard Kefford, Matthew Chan, Arthur Clements, Matteo S. Carlino, Serigne Lo, Shahneen Sandhu, Oliver Klein and Lauren E. Haydu and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.

In The Last Decade

Megan Lyle

19 papers receiving 336 citations

Peers

Countries citing papers authored by Megan Lyle

Since Specialization

Citations

This map shows the geographic impact of Megan Lyle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Megan Lyle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Megan Lyle more than expected).

Fields of papers citing papers by Megan Lyle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Megan Lyle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Megan Lyle. The network helps show where Megan Lyle may publish in the future.

Co-authorship network of co-authors of Megan Lyle

This figure shows the co-authorship network connecting the top 25 collaborators of Megan Lyle. A scholar is included among the top collaborators of Megan Lyle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Megan Lyle. Megan Lyle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	998MO Nivolumab and ipilimumab combination treatment in advanced dMMR/MSI-H noncolorectal cancers: Results from the phase II MoST-CIRCUIT study 2024 ·Annals of Oncology ·Oliver Klein, Bo Gao, Henry Chan, Michael Michael, (unknown), Jimmy Bok Yan So, S.J. Harris, Damien Kee, Ian Collins, (unknown), Megan Lyle, Craig Underhill, Martha E. Brown, Rosemary Harrup, (unknown), Jamie Palmer, (unknown), (unknown), Jonathan Cebon, (unknown)	1
2	Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study 2024 ·PLoS ONE ·Graham Cohen, Bernardo L. Rapoport, (unknown), Paul Ruff, Ana Arance, (unknown), Baerin Houghton, Michael P. Brown, (unknown), Eva Muñoz‐Couselo, Megan Lyle, James R. Anderson, Lokesh Jain, Dinesh de Alwis, Mallika Lala, (unknown), Elliot Chartash, Conrad Jacobs	0
3	Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation 2023 ·European Journal of Cancer ·Alison M. Weppler, Laetitia Da Meda, Inês Pires da Silva, Wen Xu, Giovanni Grignani, Alexander M. Menzies, Matteo S. Carlino, Georgina V. Long, Serigne Lo, Ina Nordman, Christopher Steer, Megan Lyle, Claudia Trojaniello, Paolo A. Ascierto, Célèste Lebbé, Shahneen Sandhu	14
4	Administration of immune checkpoint inhibitors at rural towns using the Teleoncology model of care—A North Queensland perspective 2023 ·Australian Journal of Rural Health ·(unknown), (unknown), (unknown), (unknown), Megan Lyle, Sabe Sabesan, Abhishek Joshi	2
5	Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade–resistant Melanoma for Anti-PD-L1 Rechallenge 2022 ·Cancer Research Communications ·André van der Westhuizen, Megan Lyle, Moira C. Graves, Xiaoqiang Zhu, Jason W.H. Wong, (unknown), (unknown), (unknown), Richard Levy, Adeeb Majid, Ricardo E. Vilain, Nikola A. Bowden	3
6	Abstract CT557: Phase 1/2 study of quavonlimab (Qmab) + pembrolizumab (pembro) in patients (pts) with advanced melanoma that progressed on a PD-1/PD-L1 inhibitor 2022 ·Cancer Research ·Sanjeev Deva, Jacek Mackiewicz, Stéphane Dalle, Helen Gogas, Iwona Ługowska, Alfonso Berrocal, Alexander M. Menzies, Michele Maio, Adnan Nagrial, (unknown), Jean‐Jacques Grob, Christian Caglevic, Megan Lyle, Juan Martín-Liberal, Rachel A. Altura, Yixin Ren, Anuradha Khilnani, (unknown), (unknown), (unknown)	2
7	Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti–PD-1 therapy 2021 ·European Journal of Cancer ·Adriana Hepner, Victoria Atkinson, James Larkin, Rebecca A. Burrell, Matteo S. Carlino, Douglas B. Johnson, Lisa Zimmer, Katy K. Tsai, Oliver Klein, Serigne Lo, Andrew Haydon, Prachi Bhave, Megan Lyle, Lalit Pallan, Inês Pires da Silva, Camille L. Gérard, Olivier Michielin, Georgina V. Long, Alexander M. Menzies	9
8	Management of resected stage III/IV melanoma with adjuvant immunotherapy. 2021 ·Journal of Clinical Oncology ·(unknown), Victoria Atkinson, Prachi Bhave, Alison M. Weppler, (unknown), (unknown), Megan Lyle, Muhammad Adnan Khattak, Andrew Haydon, Matteo S. Carlino, Shahneen Sandhu, Georgina V. Long, Alexander M. Menzies	0
9	Durability of response to immune checkpoint inhibitors (ICI) in metastatic Merkel cell carcinoma (mMCC) after treatment cessation. 2021 ·Journal of Clinical Oncology ·Alison M. Weppler, Laetitia Da Meda, Inês Pires da Silva, Wen Xu, Giovanni Grignani, Alexander M. Menzies, Matteo S. Carlino, Georgina V. Long, Ina Nordman, Christopher Steer, Megan Lyle, Claudia Trojaniello, Paolo A. Ascierto, Célèste Lebbé, Shahneen Sandhu	0
10	Multicentre retrospective assessment of toxicity and response to immunotherapy in elderly patients with metastatic melanoma. 2021 ·Journal of Clinical Oncology ·(unknown), (unknown), Robert M. Mason, (unknown), Zulfiquer Otty, Megan Lyle, Marcin Dzienis	0
11	Mortality within 30 days of receiving checkpoint inhibitor immunotherapy: An Australian multicenter review. 2020 ·Journal of Clinical Oncology ·(unknown), (unknown), (unknown), Jasotha Sanmugarajah, Megan Lyle	1
12	Activity and safety of third-line BRAF-targeted therapy (TT) following first-line TT and second-line immunotherapy (IT) in advanced melanoma. 2020 ·Journal of Clinical Oncology ·Victoria Atkinson, (unknown), Georgina V. Long, Matteo S. Carlino, (unknown), Prachi Bhave, (unknown), Wen Xu, Lauren Brown, (unknown), Megan Lyle, Alexander M. Menzies	3
13	Metastasis‐specific patterns of response and progression with anti‐PD‐1 treatment in metastatic melanoma 2017 ·Pigment Cell & Melanoma Research ·Jenny Lee, Megan Lyle, Alexander M. Menzies, Matthew Chan, Serigne Lo, Arthur Clements, Matteo S. Carlino, Richard Kefford, Georgina V. Long	35
14	The molecular profile of metastatic melanoma in Australia 2016 ·Pathology ·Megan Lyle, Lauren E. Haydu, Alexander M. Menzies, John F. Thompson, Robyn P.M. Saw, Andrew J. Spillane, Richard Kefford, Graham J. Mann, Wendy A. Cooper, Bing Yu, Richard A. Scolyer, Sandra O’Toole, Georgina V. Long	17
15	Clinicopathologic features associated with efficacy and long‐term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors 2015 ·Cancer ·Alexander M. Menzies, James S. Wilmott, Martin Drummond, Serigne Lo, Megan Lyle, Matthew Chan, John F. Thompson, Alex Guminski, Matteo S. Carlino, Richard A. Scolyer, Richard Kefford, Georgina V. Long	32
16	Patterns of acquired resistance to anti-PD-1 antibodies in patients with metastatic melanoma (MM). 2015 ·Journal of Clinical Oncology ·Jenny Lee, Adam Cooper, Megan Lyle, Elizabeth Liniker, Alexander M. Menzies, Richard Kefford, Georgina V. Long, Matteo S. Carlino	2
17	The role of systemic therapies in the management of melanoma brain metastases 2014 ·Current Opinion in Oncology ·Megan Lyle, Georgina V. Long	15
18	Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma 2014 ·Melanoma Research ·Samantha Bowyer, Aparna D. Rao, Megan Lyle, Shahneen Sandhu, Georgina V. Long, Grant A. McArthur, Jeanette Raleigh, Rodney J. Hicks, Michael Millward	57
19	Lesion-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma (MM). 2014 ·Journal of Clinical Oncology ·Megan Lyle, Jenny Lee, Alexander M. Menzies, Matthew Chan, Arthur Clements, Matteo S. Carlino, Richard Kefford, Georgina V. Long	19
20	Diagnosis and Treatment of KIT-Mutant Metastatic Melanoma 2013 ·Journal of Clinical Oncology ·Megan Lyle, Georgina V. Long	23

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact